These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23249575)

  • 1. [Targeted based therapies in metastatic breast cancer: future evolution].
    Belmondo L; Montana M; Curti C; Crozet M; Rathelot P; Penot-Ragon C; Vanelle P
    Therapie; 2012; 67(6):491-503. PubMed ID: 23249575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Second-line treatment of metastatic non-small cell lung carcinoma: What are the options today? What are the perspectives for tomorrow?].
    Greillier L; Barlesi F
    Rev Mal Respir; 2012 Jan; 29(1):4-6. PubMed ID: 22240212
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of chemotherapy and targeted agents in patients with metastatic breast cancer.
    Johnston SR
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S38-47. PubMed ID: 21944023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The next generation of biologic agents: therapeutic role in relation to existing therapies in metastatic breast cancer.
    Conte P; Guarneri V
    Clin Breast Cancer; 2012 Jun; 12(3):157-66. PubMed ID: 22607765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel agents and future directions for refractory breast cancer.
    Burstein HJ
    Semin Oncol; 2011 Jun; 38 Suppl 2():S17-24. PubMed ID: 21600381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging targeted therapies for metastatic breast cancer.
    Perez EA; Spano JP
    Cancer; 2012 Jun; 118(12):3014-25. PubMed ID: 22006669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction: Current and future approaches to chemotherapy in patients with resistant breast cancer.
    Burstein HJ
    Semin Oncol; 2011 Jun; 38 Suppl 2():S1-2. PubMed ID: 21600379
    [No Abstract]   [Full Text] [Related]  

  • 8. New cytotoxic agents and molecular-targeted therapies in the treatment of metastatic breast cancer.
    Awada A
    Forum (Genova); 2002; 12(1):4-15. PubMed ID: 12634907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chairperson's introduction: Despite significant advances in the diagnosis and treatment of breast cancer, approximately one third of patients still develop, and subsequently die from metastatic breast disease.
    Johnston SR
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S4-5. PubMed ID: 21944027
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?
    Berrada N; Delaloge S; André F
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii30-5. PubMed ID: 20943632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tracking the seed and tending the soil: evolving concepts in metastatic breast cancer.
    Comen EA
    Discov Med; 2012 Aug; 14(75):97-104. PubMed ID: 22935206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Genomics and clinical research for breast cancer].
    Bertucci F; Birnbaum D
    Med Sci (Paris); 2012 Mar; 28 Spec No 1():14-8. PubMed ID: 22494651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Major therapeutic advances and new perspectives in onco-hematology].
    Bay JO; Guièze R; Ravinet A; Lemal R; Xhaard A; Bailly S; Moluçon-Chabrot C; Hermet E; Biau J; Verrelle P; Peffault de Latour R; Tournilhac O
    Bull Cancer; 2013 Jun; 100(6):587-99. PubMed ID: 23735575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of targeted therapy in ovarian cancer.
    Banerjee S; Kaye S
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S116-30. PubMed ID: 21943965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalizing oncology: perspectives and prospects.
    Mendelsohn J
    J Clin Oncol; 2013 May; 31(15):1904-11. PubMed ID: 23589547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.
    Tkaczuk KH
    Clin Ther; 2009; 31 Pt 2():2273-89. PubMed ID: 20110041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolution of bone-targeted therapies: introduction.
    Gnant M
    Semin Oncol; 2010 Oct; 37 Suppl 2():S1. PubMed ID: 21111243
    [No Abstract]   [Full Text] [Related]  

  • 19. Awaiting a new era of cancer immunotherapy.
    Hong CW; Zeng Q
    Cancer Res; 2012 Aug; 72(15):3715-9. PubMed ID: 22815525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.